Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) CEO Oguzhan Atay sold 12,500 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $126.10, for a total transaction of $1,576,250.00. Following the completion of the sale, the chief executive officer owned 12,500 shares in the company, valued at $1,576,250. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oguzhan Atay also recently made the following trade(s):
- On Monday, July 6th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The stock was sold at an average price of $122.05, for a total transaction of $1,525,625.00.
- On Monday, July 6th, Oguzhan Atay sold 26,250 shares of Billiontoone stock. The stock was sold at an average price of $122.05, for a total value of $3,203,812.50.
- On Monday, June 8th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The stock was sold at an average price of $98.22, for a total value of $1,227,750.00.
- On Monday, June 8th, Oguzhan Atay sold 26,250 shares of Billiontoone stock. The stock was sold at an average price of $97.66, for a total value of $2,563,575.00.
Billiontoone Stock Performance
NASDAQ:BLLN opened at $129.88 on Thursday. The stock has a market cap of $5.97 billion and a P/E ratio of 236.15. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The business’s 50-day moving average price is $103.33 and its two-hundred day moving average price is $89.66. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $138.70.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the stock. BTIG Research dropped their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Guggenheim assumed coverage on Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 target price on the stock. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. upped their price objective on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.
View Our Latest Stock Analysis on BLLN
Institutional Investors Weigh In On Billiontoone
Institutional investors have recently made changes to their positions in the business. Rossby Financial LCC bought a new stake in Billiontoone in the fourth quarter worth $25,000. Wells Fargo & Company MN bought a new position in shares of Billiontoone during the fourth quarter valued at about $76,000. Smartleaf Asset Management LLC purchased a new position in shares of Billiontoone in the fourth quarter worth about $80,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Billiontoone in the 4th quarter valued at about $82,000. Finally, Renaissance Capital LLC bought a new stake in shares of Billiontoone in the 4th quarter valued at about $201,000.
Billiontoone Company Profile
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
See Also
- Five stocks we like better than Billiontoone
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
